Published in Leukemia on February 04, 2011
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J (2014) 1.30
International Myeloma Working Group recommendations for global myeloma care. Leukemia (2013) 1.10
Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur J Health Econ (2012) 1.05
Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol (2012) 1.02
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. Haematologica (2012) 0.96
European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. Haematologica (2015) 0.94
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia (2011) 0.90
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia (2014) 0.87
Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res (2012) 0.84
Treatment of relapsed and refractory multiple myeloma. Haematologica (2016) 0.83
Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. Mediterr J Hematol Infect Dis (2013) 0.80
Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. Blood Res (2015) 0.79
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. Haematologica (2015) 0.77
Current Trends of Renal Impairment in Multiple Myeloma. Kidney Dis (Basel) (2016) 0.77
Safety and efficacy of lenalidomide in relapsed or refractory multiple myeloma. Clin Med Insights Oncol (2011) 0.76
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. Blood Cancer J (2016) 0.75
Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leuk Suppl (2013) 0.75
Neurotoxicity of biologically targeted agents in pediatric cancer trials. Pediatr Neurol (2012) 0.75
Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis. PLoS One (2015) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature (1986) 4.13
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol (2000) 3.02
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica (2008) 2.99
Borna disease: a persistent virus infection of the central nervous system. Prog Med Virol (1988) 2.83
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78
Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Genomic organization of Borna disease virus. Proc Natl Acad Sci U S A (1994) 2.74
Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72
Borna disease virus, a negative-strand RNA virus, transcribes in the nucleus of infected cells. Proc Natl Acad Sci U S A (1992) 2.44
Repetitive sequences in complete and defective genomes of Herpesvirus saimiri. J Virol (1975) 2.36
Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol (1999) 2.33
Gene for alpha-chain of human T-cell receptor: location on chromosome 14 region involved in T-cell neoplasms. Science (1985) 2.33
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia (2005) 2.30
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
Borna disease virus genome transcribed and expressed in psychiatric patients. Nat Med (1995) 2.30
The challenge of biosimilars. Ann Oncol (2007) 2.28
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia (2009) 2.25
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Genetic abnormalities during transition from Helicobacter-pylori-associated gastritis to low-grade MALToma. Lancet (1995) 2.21
Identification of a common antigen of herpes simplex virus bovine herpes mammillitis virus, and B virus. J Virol (1978) 2.16
Interleukin-6 is a prognostic factor in multiple myeloma. Blood (1991) 2.16
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15
Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol (1997) 2.13
A viro-psycho-immunological disease-model of a subtype affective disorder. Pharmacopsychiatry (1998) 2.08
Serum free light chains for monitoring multiple myeloma. Br J Haematol (2004) 2.07
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00
Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia (2003) 1.96
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood (2000) 1.93
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood (1998) 1.90
Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.88
Physicochemical properties of the DNA of herpes viruses. Biochim Biophys Acta (1972) 1.86
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
Contaminations occurring in fungal PCR assays. J Clin Microbiol (1999) 1.86
Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85
First isolates of infectious human Borna disease virus from patients with mood disorders. Mol Psychiatry (1996) 1.83
A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A (1984) 1.79
A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus (1992) 1.79
Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 1.79
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant (2008) 1.78
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia (2011) 1.77
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
A simple method for measuring red cell deformability in models of the microcirculation. Blut (1973) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle. J Clin Oncol (2000) 1.73
Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst (1983) 1.72
Improved reliability of lymphoma diagnostics via PCR-based clonality testing: report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia (2006) 1.72
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Kawasaki disease in Canterbury. Arch Dis Child (1978) 1.70
Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord (2001) 1.70
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood (2011) 1.69
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia (2006) 1.69
Sequence conservation in field and experimental isolates of Borna disease virus. J Virol (1994) 1.67
Detection of new DNA polymerase genes of known and potentially novel herpesviruses by PCR with degenerate and deoxyinosine-substituted primers. Virus Genes (1999) 1.65
Amantadine and human Borna disease virus in vitro and in vivo in an infected patient with bipolar depression. Lancet (1997) 1.62
Persistent, tolerant or subacute infection in Borna disease virus-infected rats. J Gen Virol (1983) 1.62
Cerebrovascular tone rather than intracranial pressure determines the effective downstream pressure of the cerebral circulation in the absence of intracranial hypertension. J Neurosurg Anesthesiol (2000) 1.61
Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol (1998) 1.61